ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

SNA02-48

A development code.

Its studies are mostly in Tetanus, led by Sinovac Biotech.

Furthest: phase 3, since Jun 2, 20262 company-led studies, 1 open or runningNext primary completion: Mar 31, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sinovac Biotech21 open or runningphase 3since Jun 2, 2026Apr 15, 2025Mar 31, 2027phase 3 · NCT07633119

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 15, 2025First study: phase 2 study in TetanusFirst studyNCT06939777 · 255 enrolled · China
  2. Jun 2, 2026Phase 3 study in TetanusPhase 3 reachedNCT07633119 · 600 planned · China

Ahead

  1. Mar 31, 2027Primary completion: phase 3 study in TetanusNCT07633119

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07633119Tetanus · China3Not yet recruitingMar 31, 2027600
NCT06939777Tetanus · China2CompletedDec 8, 2025255

How it is read

Names in the registry

  • “SNA02-48”, 2 entries

Codes read as this program: SNA0248.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.